v3.26.1
Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited)
₪ in Thousands, $ in Thousands
 6 Months Ended
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2026
ILS (₪)
₪ / shares
shares
Jun. 30, 2025
ILS (₪)
₪ / shares
shares
Profit or loss [abstract]      
Revenues $ 2,042 ₪ 6,080 ₪ 3,999
Cost of revenues 1,294 3,855 2,542
Total revenues 748 2,225 1,457
Research and development expenses, net 2,840 8,459 8,029
Sales and marketing expenses 2,143 6,382 5,966
General and administrative expenses 2,734 8,141 8,083
Operating loss 6,969 20,757 20,621
Financial expenses 5,359 15,962 4,766
Financial income (553) (1,647) (2,231)
Financial expenses (income), net 4,806 14,315 2,535
Loss before income tax 11,775 35,072 23,156
Provision (benefit) for income tax 1
Net loss and comprehensive loss $ 11,775 ₪ 35,072 ₪ 23,157
Loss per ordinary share - basic | (per share) [1] $ 1.83 ₪ 5.39 ₪ 3.6
Loss per ordinary share - diluted | (per share) [1] $ 1.83 ₪ 5.39 ₪ 3.6
Weighted average ordinary shares outstanding - basic 6,502,844 6,502,844 6,429,059
Weighted average ordinary shares outstanding - diluted 6,502,844 6,502,844 6,429,059
[1] Basic loss per share does not include the above-mentioned 1,562,500 pre-funded warrants since they are accounted for as a liability. In addition, the impact of the pre-funded warrants has not taken in the diluted weighted average number of ordinary shares calculation as their effect would have been anti-dilutive.